Royalty Pharma plc
RPRX
Rangering i aksjer
#892
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aksjekurs
$60.39
Sist synkronisert: 2026-10-19
Markedsverdi
$26.89B
Endring (1 dag)
-0.93%
Endring (1 år)
64.87%
Land
US
Handel Royalty Pharma plc (RPRX)
Kategori
Healthcare
EPS for Royalty Pharma plc (RPRX)
EPS per June 2026 TTM: $2.41
Ifølge de siste økonomiske rapportene og aksjekursen til Royalty Pharma plc er selskapets nåværende EPS (TTM) $2.41. Ved slutten av 2024 hadde selskapet en EPS på $1.92, en nedgang sammenlignet med EPS-en i 2023 som var $2.54.
EPS-historikk for Royalty Pharma plc fra 2015 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $2.41 | 34.64% |
| 2025 | $1.79 | -6.61% |
| 2024 | $1.92 | -24.41% |
| 2023 | $2.54 | 2,492.43% |
| 2022 | $0.10 | -93.45% |
| 2021 | $1.49 | -42.47% |
| 2020 | $2.60 | -59.54% |
| 2019 | $6.42 | 182.80% |
| 2018 | $2.27 | 13.86% |
| 2017 | $1.99 | 113.83% |
| 2016 | $0.93 | -2.67% |
| 2015 | $0.96 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -99.22% |
HK
|
|
| $0.52 | -78.42% |
US
|
